Isomorphic Labs secures $5 billion in new funding round
Isomorphic Labs, an AI drug discovery company led by Sir Demis Hassabis, has raised $5 billion in a Series C round.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Isomorphic Labs, an AI drug discovery company led by Sir Demis Hassabis, has raised $5 billion in a Series C round. The funding comes just six months after a $2.1 billion round. The company plans to use the money to move its drug pipeline toward clinical trials.
Why it matters
The company has no approved drugs yet, so the funding is meant to push its pipeline forward. The reports describe the round as a record for AI in biology.
Coverage
- Sir Demis Hassabis raises $5bn for AI drug discovery company (The Telegraph)
- Analysis: 3 thoughts on Isomorphic's record $5B Series C for AI in bio (endpoints.news)
- Isomorphic Labs raises $5 billion for AI drug development (ua.news)
- AI drug discovery giant Isomorphic Labs raises €4.5 billion in blockbuster funding round (David Cendon Garcia)
- Isomorphic Labs raises $5 billion in its second mega-round within six months (the-decoder.com)
- Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO (CNBC)
- Google's Isomorphic Labs Raises $5 Billion Series C From Greenoaks And Sequoia Capital (OfficeChai Team)
- He sold DeepMind to Google. Now his London AI firm is worth $50bn (thetimes.com)
- AI drugmaker Isomorphic restocks with $5B fundraise (biopharmadive.com)
More from Technology & AI
- China puts humanoid robots to work serving food and sorting parcels
- Newsom proposes sweeping AI safety rules for Washington
- Google releases Gemini 4 Neon AI model with million-token context
- Microsoft and Intel widen their cloud chip partnership
- Google DeepMind rolls out Genie 4 to select subscribers
- AI helped AMD shorten chip design work, OpenAI says